InDex Pharmaceuticals Holding AB
STO:FLERIE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.8
55.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InDex Pharmaceuticals Holding AB
Additional Paid In Capital
InDex Pharmaceuticals Holding AB
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Additional Paid In Capital
kr5.5B
|
CAGR 3-Years
85%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Camurus AB
STO:CAMX
|
Additional Paid In Capital
kr3.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
||
S
|
Swedencare AB (publ)
STO:SECARE
|
Additional Paid In Capital
kr6.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Additional Paid In Capital
kr690.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
||
Moberg Pharma AB (publ)
STO:MOB
|
Additional Paid In Capital
kr921.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
InDex Pharmaceuticals Holding AB
Glance View
InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
See Also
What is InDex Pharmaceuticals Holding AB's Additional Paid In Capital?
Additional Paid In Capital
5.5B
SEK
Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Additional Paid In Capital amounts to 5.5B SEK.
What is InDex Pharmaceuticals Holding AB's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
74%
Over the last year, the Additional Paid In Capital growth was 536%. The average annual Additional Paid In Capital growth rates for InDex Pharmaceuticals Holding AB have been 85% over the past three years , 74% over the past five years .